Video

David Gershenson on Challenges to Advancing Treatment for Rare Ovarian Cancers

Author(s):

David Gershenson, M.D.
Conference|Ovarian Cancer National Conference

David Gershenson, M.D., of MD Anderson Cancer Center, explains the difficulty of advancing treatment of rare ovarian cancers: malignant ovarian germ cell tumors, sex cord stromal tumors, and types of epithelial tumors such as ovarian clear cell carcinoma, ovarian low-grade serous carcinoma, and mucinous tumors.

David Gershenson, M.D., of MD Anderson Cancer Center, explains the difficulty of advancing treatment of rare ovarian cancers: malignant ovarian germ cell tumors, sex cord stromal tumors, and types of epithelial tumors such as ovarian clear cell carcinoma, ovarian low-grade serous carcinoma, and mucinous tumors. With such a low number of cases and not much interest from pharmaceutical companies, it is hard to conduct clinical trials in these areas.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Dr. Elizabeth K. Lee discusses the RAINFOL-01 clinical trial evaluating treatment with Rina-S in advanced ovarian cancer.
Image of woman.
Image of smiling doctor.
Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.
Dr. Debu Tripathy highlights the importance of staying informed on breast cancer advancements and how this empowers patients to make informed decisions.
Image of woman with blonde hair.
Image of woman with blonde hair.
Image of woman with brown hair.
Image of doctor with brown hair.
Image of Doctor with blonde hair.
Related Content
MATTHEW MANGOLD, B.S.N., RN, and ERIN LONGSTRETH, M.S.N., RN, OCN, NEA-BC
April 22nd 2025

Advocacy and ‘Radiating Valor’ Have a Transformative Impact

Erin Longstreth, M.S.N., RN, OCN, NEA-BC
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate cancer.
April 15th 2025

Erleada Reduces Risk of Death in Metastatic Prostate Cancer Subset

Ashley Chan
Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate cancer.
cancer horizons image for podcast
December 14th 2023

Conference Highlights from the 2023 ASH Annual Meeting

Brielle Benyon Alex Biese
CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.
Image of man holding stomach.
April 6th 2025

FDA Grants HLX22 Orphan Drug Designation for Gastric Cancer

Spencer Feldman
FDA grants orphan drug designation to HLX22 for gastric cancer, with a phase 2 trial showing improved progression-free survival and objective response.
Image of plasma cells.
April 4th 2025

Overcoming Challenges and Advancing CAR-T Therapy for Myeloma

Spencer Feldman
CAR-T therapy for myeloma faces challenges in early-line use due to accessibility, eligibility criteria and long wait times, despite strong efficacy in trials.